Morgan Stanley Maintains Underweight on Veracyte, Lowers Price Target to $37
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:VCYT) with a Underweight and lowers the price target from $48 to $37.
Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:VCYT) with a Underweight and lowers the price target from $48 to $37.